PROKIDNEY CP (PROK)
(Delayed Data from NSDQ)
$2.30 USD
+0.18 (8.49%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $2.30 0.00 (0.00%) 7:54 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
PROK 2.30 +0.18(8.49%)
Will PROK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PROK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PROK
Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now
After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)
PROK: What are Zacks experts saying now?
Zacks Private Portfolio Services
ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for PROK
Commit To Buy ProKidney Corp At $2.50, Earn 50.1% Annualized Using Options
12 Health Care Stocks Moving In Monday's Intraday Session
Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers
Veru, EyePoint Pharmaceuticals, Sintx Technologies among healthcare movers
Veru, EyePoint Pharmaceuticals, SINTX Technologies among healthcare movers